UK-based biotech SynaptixBio has secured a second Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA). The company received its first ODD in early 2023 for a therapeutic that targets Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC), the most severe form of TUBB4A leukodystrophy. This second ODD allows research […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!